Immunogenicity and safety of the 13-valent pneumococcal conjugate vaccine in patients with immunocompromising conditions: a review of available evidence

Immunocompromising conditions increase the risk of invasive pneumococcal disease (IPD). Vaccine uptake in patients with these conditions may be low in part because of concerns about decreased immunogenicity and safety in these high-risk groups. We conducted a literature search to identify publicatio...

Full description

Bibliographic Details

Published in:	Human Vaccines & Immunotherapeutics
Main Authors:	Erica Chilson, Daniel A. Scott, Beate Schmoele-Thoma, Wendy Watson, Mary M. Moran, Raul Isturiz
Format:	Article
Language:	English
Published:	Taylor & Francis Group 2020-11-01
Subjects:	pcv13 invasive pneumococcal disease vaccination immunocompromised high-risk immunogenicity
Online Access:	http://dx.doi.org/10.1080/21645515.2020.1735224